Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes

Journal of Clinical Pharmacology

Volumn 53, Issue 6, 2013, Pages 670-674

  Ebbesen, Maria S ^a   Nersting, Jacob ^a   Jacobsen, Jack H ^a   Frandsen, Thomas L ^a   Vettenranta, Kim ^b   Abramsson, Jonas ^c   Wesenberg, Finn ^d   Schmiegelow, Kjeld ^a,e  

^a Rigshospitalet   (Denmark)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute lymphoblastic leukemia; DNA TG; Maintenance therapy; Thiopurine methyltransferase; Thiopurines

Indexed keywords

DEXAMETHASONE; DNA; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; MAINTENANCE THERAPY; MALE; METABOLITE;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DNA; FEMALE; GENOTYPE; GUANINE NUCLEOTIDES; HUMANS; MALE; METHOTREXATE; METHYLTRANSFERASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THIONUCLEOTIDES;

EID: 84880252801     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.81     Document Type: Article

References (27)

1. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008;30:831-849.
2. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343: 1188-1190.
3. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol 2010;79:1211- 1220.
4. Schmiegelow K, Al Modhwahi I, Andersen MK, et al. Methotrexate/6 mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia - results from the NOPHO ALL 92 study. Blood 2009; 113:6077-6084.
5. Lennard L, Welch JC, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 1997;44:455-461.
6. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy related cancer. Nat Rev Cancer 2008;8:24-36.
7. Waters TR, Swann PF. Cytotoxic mechanism of 6 thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6 methylthioguanine. Biochemistry 1997;36: 2501-2506.
8. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-391.
9. Bokkerink JP, Stet EH, De Abreu RA, et al. 6 Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant Tlymphoblasts. Biochem Pharmacol 1993;45:1455-1463.
10. Hedeland RL, Hvidt K, Nersting J, et al. DNA incorporation of 6 thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non Hodgkin lymphoma. Cancer Chemother Pharmacol 2010;66:485-491.
11. Wang L, Weinshilboum R. Thiopurine S methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006;25:1629-1638.
12. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149- 154.
13. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6 thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
14. Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL 92 study. Leukemia 2009;23:557-564.
15. www.clinicaltrials.gov. Trial numbers: NCT 0098 2514, NCT00548431, NCT01272440, NCT01305655, NCT00819351 and NCT00816049.
16. Schmiegelow K, Forestier E, Hellebostad M, et al. Long term results of NOPHO ALL 92 and ALL 2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24:345-354.
17. Bruunshuus I, Schmiegelow K. Analysis of 6 mercaptopurine, 6 thioguanine nucleotides, and 6 thiouric acid in biological fluids by high performance liquid chromatography. Scand J Clin Lab Invest 1989;49:779-784.
18. Jacobsen JH, Schmiegelow K, Nersting J. Liquid chromatographytandem mass spectrometry quantification of 6 thioguanine in DNA using endogenous guanine as internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 2012;881-882:115-118.
19. Thomsen JB, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6 mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999;86:1080-1086.
20. Harms DO, Gobel U, Spaar HJ, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL 92. Blood 2003;102:2736-2740.
21. Escherich G, Richards S, Stork LC, Vora AJ. Meta analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia 2011;25:953-959.
22. Jacobs SS, Stork LC, Bostrom BC, et al. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG 1942). Pediatr Blood Cancer 2007;49:250-255.
23. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6 thioguanine versus 6 mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-1348.
24. Bergan S, Bentdal O, Sodal G, Brun A, Rugstad HE, Stokke O. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 1997;19:502-509.
25. Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998;102:439-443.
26. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332-1339.
27. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34-39.